Damora Therapeutics, Inc. (DMRA)Healthcare | Biotechnology | Waltham, United States | NasdaqCM
26.60 USD
-0.40
(-1.481%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 26.60 Short-term: ★★★★☆ | Long-term: ★★★★★ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:03 a.m. EDT
Damora Therapeutics (DMRA) is experiencing a critical pivot moment; the appointment of a new CEO, a $535M cash reserve to fund lead programs through Phase 3, and significant equity awards signal strong institutional confidence in the pipeline. The stock has shed its value-trap characteristics (negative EPS/Book) as it transitions into clinical certainty, offering a high-conviction long-term play despite short-term volatility. However, with no dividend history and negative free cash flow, this is purely a growth vehicle. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.093763 |
| AutoETS | 0.105914 |
| AutoTheta | 0.106178 |
| MSTL | 0.122701 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 76% |
| H-stat | 1.10 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.854 |
| Excess Kurtosis | -0.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.028 |
| Market Cap | 1,604,065,408 |
| Beta | 1.60 |
| Previous Name | Galecto, Inc. |
| Website | https://www.damoratx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 9.991735 |
| Address1 | Building 23 |
| Address2 | Suite 105 221 Crescent Street |
| All Time High | 449.75 |
| All Time Low | 2.01 |
| Ask | 27.4 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 287,300 |
| Average Daily Volume3 Month | 285,798 |
| Average Volume | 285,798 |
| Average Volume10Days | 287,300 |
| Beta | 1.598 |
| Bid | 26.24 |
| Bid Size | 1 |
| Book Value | -110.105 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 26.6 |
| Current Ratio | 12.978 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 27.925 |
| Day Low | 26.29 |
| Debt To Equity | 0.028 |
| Display Name | Damora Therapeutics |
| Ebitda | -36,540,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -48.242 |
| Enterprise Value | 1,762,762,496 |
| Eps Trailing Twelve Months | -3.98 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 26.3638 |
| Fifty Day Average Change | 0.23620033 |
| Fifty Day Average Change Percent | 0.008959267 |
| Fifty Two Week Change Percent | 999.1735 |
| Fifty Two Week High | 38.325 |
| Fifty Two Week High Change | -11.725 |
| Fifty Two Week High Change Percent | -0.30593607 |
| Fifty Two Week Low | 2.36 |
| Fifty Two Week Low Change | 24.24 |
| Fifty Two Week Low Change Percent | 10.271187 |
| Fifty Two Week Range | 2.36 - 38.325 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,603,978,200,000 |
| Float Shares | 47,600,340 |
| Free Cashflow | -3,049,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 7 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0146200005 |
| Held Percent Institutions | 0.08116 |
| Implied Shares Outstanding | 60,303,212 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,976,000 |
| Last Split Factor | 1:25 |
| Long Business Summary | Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts. |
| Long Name | Damora Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,604,065,408 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_154090027 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | -209,839,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,604,065,439 |
| Number Of Analyst Opinions | 5 |
| Open | 27.85 |
| Operating Cashflow | -6,726,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 781 281 9020 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 26.6 |
| Post Market Time | 1,776,460,645 |
| Prev Name | Galecto, Inc. |
| Previous Close | 27.0 |
| Price Hint | 2 |
| Price To Book | -0.24158756 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.884 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.4 |
| Regular Market Change Percent | -1.48148 |
| Regular Market Day High | 27.925 |
| Regular Market Day Low | 26.29 |
| Regular Market Day Range | 26.29 - 27.925 |
| Regular Market Open | 27.85 |
| Regular Market Previous Close | 27.0 |
| Regular Market Price | 26.6 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 380,735 |
| Return On Assets | -0.16459998 |
| Return On Equity | -1.63802 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 60,303,212 |
| Shares Percent Shares Out | 0.0137 |
| Shares Short | 827,221 |
| Shares Short Previous Month Date | 1,770,940,800 |
| Shares Short Prior Month | 277,004 |
| Short Name | Damora Therapeutics, Inc. |
| Short Percent Of Float | 0.0138 |
| Short Ratio | 2.98 |
| Source Interval | 15 |
| State | MA |
| Symbol | DMRA |
| Target High Price | 55.0 |
| Target Low Price | 40.0 |
| Target Mean Price | 46.2 |
| Target Median Price | 45.0 |
| Total Cash | 257,624,000 |
| Total Cash Per Share | 4.272 |
| Total Debt | 68,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.98 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 16.020725 |
| Two Hundred Day Average Change | 10.579275 |
| Two Hundred Day Average Change Percent | 0.6603493 |
| Type Disp | Equity |
| Volume | 380,735 |
| Website | https://www.damoratx.com |
| Zip | 2,453 |